01/01/1994 - "Ximoprofen is a new propionic NSAID which has previously demonstrated its efficacy at a daily dose of 30 mg. The aim of the study was to evaluate the efficacy of different daily dosages of Ximoprofen in patients with active ankylosing spondylitis. "
01/01/1994 - "Ximoprofen in ankylosing spondylitis. "
01/01/1994 - "This study 1/confirms the efficacy of Ximoprofen at a 30 mg daily dosage, 2/shows the persistence of this efficacy at lower dosages, 3/suggests that ankylosing spondylitis is a sensitive and relevant human model to assess NSAIDs at an early stage of clinical evaluation."
|1.||Non-Steroidal Anti-Inflammatory Agents (NSAIDs)